Surendra Kolla, MD
Urology · Wichita, KSNPI 1194952143
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (42.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Teleflex LLC at 39.5% of the total. Reporting peaked in 2022 at $1,156 and has fallen 71.1% since, to $334 in 2025. That places this record below the midpoint for urology clinicians in KS, where the typical reported total is $2,717.
Across 61 payments — averaging $44.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Astellas Pharma US Inc$245
- C. R. Bard, Inc. & Subsidiaries$211
- Intuitive Surgical$210
- Medtronic$190
- Immunitybio, Inc.$124
- plus $663 from 18 others
What the payments were for
- Consulting fees$1907%
- Speaking & faculty fees$38514%
- Travel & lodging$78029%
- Food & beverage$1,15643%
- Education$2068%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 5 | $1,074 |
| Astellas Pharma US Inc | 8 | $245 |
| C. R. Bard, Inc. & Subsidiaries | 5 | $211 |
| Intuitive Surgical | 3 | $210 |
| Medtronic | 5 | $190 |
| Immunitybio, Inc. | 1 | $124 |
| Dendreon Pharmaceuticals LLC | 4 | $111 |
| Pfizer | 4 | $99 |
| Rochester Medical Corporation | 3 | $48 |
| Calyxo, Inc. | 2 | $44 |
| AbbVie(2 entities) | 2 | $42 |
| Urogen Pharma, Inc. | 2 | $41 |
| BD | 2 | $40 |
| Coloplast | 3 | $38 |
| Travere Therapeutics, Inc. | 3 | $33 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Angiodynamics, Inc. | 1 | $23 |
| Antares Pharma, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$1,062
- DA VINCI SP$150
- ANKTIVA$124
How this compares
$2,717 in reported general payments places this provider in the 50th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 24 | $335,523 |
| OrgovyxRelugolix | 38 | $98,324 |
| MyrbetriqMirabegron | 104 | $70,515 |
| GemtesaVibegron | 79 | $42,884 |
| Tamsulosin Hcl | 492 | $5,095 |
| Tolterodine Tartrate ErTolterodine Tartrate | 40 | $4,264 |
| Oxybutynin Chloride ErOxybutynin Chloride | 103 | $2,800 |
| Finasteride | 248 | $1,989 |
| Solifenacin Succinate | 26 | $1,755 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 27 | $649 |
| Methenamine Hippurate | 26 | $581 |
| Cefdinir | 30 | $401 |
| Trimethoprim | 12 | $299 |
| Oxybutynin Chloride | 35 | $291 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 46 | $265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $245 | $406,038128 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $26 | $141,208117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 111 urology providers in Kansas.
Other urology in Wichita
- Timothy RichardsonWichita$493K
- Gregory ByrdWichita$18K
- Philippe NabboutWichita$13K
- Fadi JoudiWichita$12K
- Ayham FarhaWichita$8K
- Jeffrey DavisWichita$8K
- James GilbaughWichita$5K
- Jonathan JensenWichita$4K
- George ZakhariaWichita$3K
- Kahlil SaadWichita$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.